US payers are interested in incorporating real-world evidence (RWE) into their pharmaceutical coverage and reimbursement decisions. One barrier to using RWE to inform decisions is the lack of standards for RWE assessment and interpretation specific to US payer needs.
Lockhart et al. (2025) studied this question.